-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Olverembatinib in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Olverembatinib in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drug Details:Olverembatinib is a third generation, ponatinib...
-
Product Insights
![]()
Omicron Consul./ Telus Corp – Nanaimo Rental Community – British Columbia
Equip yourself with the essential tools needed to make informed and profitable decisions with our Omicron Consul./ Telus Corp - Nanaimo Rental Community - British Columbia report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
![]()
Net Present Value Model: IMMBCP-01
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model IMMBCP-01 Drug Details IMMBCP-01 is under...
-
Product Insights
![]()
Net Present Value Model: VLA-2001
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model VLA-2001 Drug Details Coronavirus Disease 2019...
-
Product Insights
![]()
Net Present Value Model: Coronavirus Disease 2019 (COVID-19) vaccines
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Coronavirus Disease 2019 (COVID-19) vaccines Drug...
-
Product Insights
![]()
Net Present Value Model: Xevudy
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Xevudy Drug Details Sotrovimab is a...
-
Product Insights
![]()
Net Present Value Model: Olverembatinib
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Olverembatinib Drug Details Olverembatinib is a...
-
Product Insights
![]()
Net Present Value Model: Comirnaty
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Comirnaty Drug Details Tozinameran (Comirnaty, COVID-19...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – olverembatinib
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry olverembatinib Drug Details Olverembatinib is a third generation, ponatinib analog that acts by targeting...
-
Product Insights
![]()
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Cathepsin L1 plays a major role in antigen processing, tumor invasion and metastasis, bone resorption, and turnover of intracellular and secreted proteins involved in growth regulation. Cathepsin L promotes tumor cell invasion and metastasis by catalyzing the degradation of the interstitial matrix and basement membranes, thus allowing cancer cells to invade locally and metastasize to distant sites. The Cathepsin L1 pipeline market research report provides comprehensive information on the Cathepsin L1 targeted therapeutics, complete with analysis by indications, stage of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.